0001023024-26-000034
SEC filingANI Pharmaceuticals, Inc. dismissed EisnerAmper LLP as its independent auditor and appointed Ernst & Young LLP as its new auditor, effective April 1, 2026, with no disagreements or adverse opinions reported.
ANI Pharmaceuticals effected a routine change in its independent registered public accounting firm on April 1, 2026, dismissing EisnerAmper LLP and appointing Ernst & Young LLP, both approved by the Audit and Finance Committee. The transition appears smooth, as EisnerAmper's audit reports for the fiscal years ended December 31, 2024, and 2025 contained no adverse opinions, disclaimers, qualifications, or modifications related to uncertainty, audit scope, or accounting principles. Critically, there were no disagreements with EisnerAmper during those periods or the interim through the dismissal date. Additionally, no consultations occurred with EY regarding accounting, audit scope, or reportable events matters prior to the appointment. EisnerAmper's letter in Exhibit 16.1 affirms agreement with the disclosures concerning their engagement, signaling no disputes. This change may reflect strategic preferences for EY's expertise ahead of the 2026 fiscal year audit, with no immediate red flags for investors.